ClinicalTrials.Veeva

Menu
E

Excell Research, Inc | Oceanside, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atogepant
Lurasidone
Rapastinel
Cariprazine
KarXT
Armodafinil
Eszopiclone
Divalproex
JNJ-42847922
Bitopertin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 106 total trials

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accept...

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: SEP-363856

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Placebo
Drug: Azetukalner

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant
Locations recently updated

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompa...

Enrolling
Chronic Migraine
Drug: Atogepant
Drug: Placebo for Atogepant

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Placebo-Matching Atogepant
Drug: Atogepant

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is t...

Active, not recruiting
Depressive Disorder, Major
Drug: Placebo matching BI 1569912
Drug: BI 1569912

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole
Locations recently updated

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only
Migraine Prophylaxis
Drug: Atogepant

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how saf...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo for ABBV-932
Drug: ABBV-932

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

Sumitomo Pharma logo
AbbVie logo
Allergan logo
Otsuka logo
Janssen (J&J Innovative Medicine) logo
Allergan logo
Tonix Pharmaceuticals logo
Astellas logo
Biogen logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems